Latest Financial Results

Q2 2019

Quarterly Results

Ended Apr 30, 2019

Stock Information

Symbol

ANIX

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Anixa is focused on harnessing the body’s immune system in the fight against cancer.  Anixa’s therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease.  Anixa’s diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the body’s immune response to the presence of a malignancy.  Anixa continually examines emerging technologies in complementary fields for further development and commercialization. 

Logo Itus

Latest News & Events

Anixa Biosciences Announces VA North Texas Health Care System to Join Cchek™ Prostate Cancer Study

Read More...

Anixa Biosciences Announces Additional Patent Issued on Cancer Detection Technology

Read More...

Anixa Biosciences Announces U.S. Department of Veterans Affairs VA Maryland Health Care System Joins Cchek™ Prostate Cancer Study

Read More...

Cancer Fact: Approximately 40 million mammograms are conducted annually.